Latanoprost Sandoz

Latanoprost, the active ingredient in Latanoprost Sandoz, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intraocular pressure and is used to treat open-angle glaucoma and ocular hypertension in adults. GNH USA supplies Latanoprost Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost Sandoz belongs to the prostaglandin analog class and is used to manage ocular conditions characterized by elevated intraocular pressure.

Open‑angle glaucoma: reduces intraocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent development of glaucoma.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia - Increased eyelash length and thickness - Darkening of the iris color - Eye irritation or foreign‑body sensation - Blurred vision shortly after instillation - Mild ocular discomfort

Serious or Rare Side Effects: - Severe eye inflammation (uveitis) - Allergic reaction with swelling or rash - Sudden increase in intraocular pressure - Corneal edema or clouding - Vision loss or significant visual disturbance - Persistent eye pain

Before using Latanoprost Sandoz, consider the following safety measures.

Pregnancy: safety not established; avoid unless benefit outweighs risk. Breastfeeding: unknown safety; use only if clearly needed. Active ocular infection: contraindicated until infection resolved. Contact lens wear: avoid wearing lenses for several hours after instillation. Monitoring: regular intraocular pressure checks are essential. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Nonsteroidal anti‑inflammatory eye drops: may diminish IOP‑lowering effect. - Other prostaglandin analogs: additive IOP reduction can increase risk of side effects.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: combined use may lead to excessive IOP reduction. - Carbonic anhydrase inhibitor eye drops: may enhance hypotensive effect. - Systemic carbonic anhydrase inhibitors: monitor intraocular pressure for additive effect.